@article{3ede24295f1c42fcbe6a7e34cdca79e4,
title = "The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis",
abstract = "Chronic inflammation is a hallmark of atherosclerosis, but its transcriptional underpinnings are poorly understood. We show that the transcriptional repressor Bcl6 is an anti-inflammatory regulator whose loss in bone marrow of Ldlr -/- mice results in severe atherosclerosis and xanthomatous tendonitis, a virtually pathognomonic complication in patients with familial hypercholesterolemia. Disruption of the interaction between Bcl6 and SMRT or NCoR with a peptide inhibitor in vitro recapitulated atherogenic gene changes in mice transplanted with Bcl6-deficient bone marrow, pointing to these cofactors as key mediators of Bcl6 inflammatory suppression. Using ChIP-seq, we reveal the SMRT and NCoR corepressor cistromes, each consisting of over 30,000 binding sites with a nearly 50% overlap. While the complete cistromes identify a diversity of signaling pathways, the Bcl6-bound subcistromes for each corepressor are highly enriched for NF-κB-driven inflammatory and tissue remodeling genes. These results reveal that Bcl6-SMRT/NCoR complexes constrain immune responses and contribute to the prevention of atherosclerosis.",
author = "Barish, {Grant D.} and Yu, {Ruth T.} and Karunasiri, {Malith S.} and Diana Becerra and Jason Kim and Tseng, {Tiffany W.} and Tai, {Li Jung} and Matthias Leblanc and Cody Diehl and Leandro Cerchietti and Miller, {Yury I.} and Witztum, {Joseph L.} and Melnick, {Ari M.} and Dent, {Alexander L.} and Tangirala, {Rajendra K.} and Evans, {Ronald M.}",
note = "Funding Information: We thank S. Ganley and E. Ong for administrative assistance, J. Ecker and J. Nery for assistance with DNA sequencing, J. Vaughan for help with antibody development, Dr. Caroline van Stijn for technical help, and M. Barish for critical reading. This work was funded by National Institutes of Health (NIH) grants K08HL092298 (G.D.B.), P01HL088093 (R.M.E.), U19DK062434 (R.M.E.), R37DK057978 (R.M.E.), R01HD027183 (R.M.E.), CA014195-38 (R.M.E.), R01HL086566 (R.K.T.), and P30DK063491/DERC Core (R.K.T.); and by support from Dr. Alan Fogelman and the David Geffen School of Medicine at UCLA Department of Medicine (R.K.T.), the Samuel Waxman Cancer Research Foundation (R.M.E.), the Chapman Foundation (R.M.E.), and the Howard Hughes Medical Institute (R.M.E.). R.M.E. is an investigator of the Howard Hughes Medical Institute and is March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute for Biological Studies. ",
year = "2012",
month = apr,
day = "4",
doi = "10.1016/j.cmet.2012.02.012",
language = "English (US)",
volume = "15",
pages = "554--562",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "4",
}